FDA approves saliva-based coronavirus test viewed as 'major game changer'


The Food and Drug Administration on Saturday issued an emergency use authorization for the SalivaDirect COVID-19 diagnostic test developed by the Yale School of Public Health.
The test, which processes saliva samples to rapidly determine whether a person is infected with the coronavirus and does not require any type of swab or specific collection device, could be one of the first "major game changers in fighting the pandemic," said Andy Slavitt, a former acting administrator of the Centers for Medicare and Medicaid Services under the Obama administration, in a Twitter thread.
For starters, the process should be a lot more comfortable for people. It doesn't, as Slavitt puts it, require sticking "something four inches up a kid's nostril." But besides being painless, it's affordable — the materials are about $4, Slavitt said, and even when adding the cost of labor and overhead, its development is still cheaper than current tests.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
And, because it's cheap and has a fast turnaround time, people will likely be able to get tested more frequently, which will in turn increase diagnostic accuracy.
Slavitt believes all of these assets could especially come in handy for schools, universities, and office buildings which theoretically need to ramp up testing if they want to re-open safely. It could also encourage more asymptomatic people to get tested.
The final reason Slavitt has high praise for the test isn't about the science. Instead, he pointed out that Yale, in partnership with the NBA, developed the test without any intention of making a profit. Tim O'Donnell
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
June 28 editorial cartoons
Cartoons Saturday's political cartoons include stupid wars, a critical media, and mask standards
-
Thai fish pie with crispy turmeric potatoes recipe
The Week Recommends Tasty twist on the Lancashire hot pot is given a golden glow
-
Palestine Action: protesters or terrorists?
Talking Point Damaging RAF equipment at Brize Norton blurs line between activism and sabotage, but proscription is a drastic step
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia